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Introduction
Catheter ablations of cardiac arrhythmias are traditionally performed using fluoroscopic guidance for catheter placement. It has been well established that radiation exposure increases the lifetime risk of malignancies, genetic defects, skin injuries, and cataracts. [1] [2] [3] [4] [5] [6] In addition, orthopedic maladies attributed to the use of heavy protective lead apparel have been documented. 7 Ablations can be of long duration, with an average effective radiation dose of 15 mSv, the equivalent of 150 chest x-rays. 8 Studies have shown the radiation exposure received from 53 minutes to 60 minutes of fluoroscopy during ablation procedures might result in 0.7-1.4 fatal malignancies per 1,000 women and 1.0-2.6 per 1,000 men. 9, 10 While the total fluoroscopy time is not as good a predictor of radiation-related malignancies as the total radiation dose, nonetheless efforts to decrease the fluoroscopy time should be considered.
Newer imaging and mapping techniques have reduced fluoroscopy times. Pulse fluoroscopy and optimization of fluoroscopy exposure parameters have also led to a reduction in radiation burden. 9 The data with regard to elimination of fluoroscopy during cardiac ablations in the adult population are sparse, mostly limited to single case reports. [11] [12] [13] [14] [15] [16] We have previously published a case-control study comparing nonfluoroscopic and fluoroscopic-guided catheter ablations in 120 patients. 17 These results demonstrated that nonfluoroscopic catheter ablations could be safely and effectively performed in adults with a variety of arrhythmias relying only on intracardiac electrograms (IE), electroanatomic mapping (EAM), and in most instances intracardiac echocardiography (ICE), for catheter guidance. 17 Herein, we present our 5-year safety, efficacy, and feasibility data of fluoroless catheter ablations of cardiac arrhythmias. To our knowledge this is the largest experience on this subject that has yet been published.
Methods
A retrospective analysis was conducted, following institutional review board approval, examining cardiac catheter ablation procedures performed without fluoroscopy.
We performed nonfluoroscopic catheter ablations on 500 consecutive patients from December 2010 through March 2016. The reported patients were consecutive and no one was excluded from this technique for endocardial catheter ablation. Some patients underwent ablations for more than one arrhythmia during their procedure, for a total of 639 arrhythmias ablated. Procedural success and recurrences were counted for each arrhythmia type (n = 639), while complications were counted for each procedure (n = 500). In an effort to establish an accurate assessment of procedural duration for any given arrhythmia ablation, the duration of the procedure was counted only for those in whom there was only one arrhythmia ablated. Procedure length was defined as the time interval from initial venous or arterial access until removal of all sheaths at the conclusion of the case. All patients were informed about the risks, benefits, and alternatives of nonfluoroscopic catheter ablation and informed consent was obtained prior to each procedure.
Procedures were classified as ablation for: atrioventricular reciprocating tachycardia (AVRT), atrioventricular nodal reentrant tachycardia (AVNRT), atrial fibrillation (AF), premature ventricular contractions (PVCs), and ventricular tachycardia (VT). Atrial tachycardias (ATs) were divided into macro-reentrant AT (such as cavotricuspid isthmus dependent flutters and others) and focal AT. In this analysis, no distinction was made with regard to paroxysmal AF versus persistent AF and longstanding persistent AF. Additional arrhythmias encountered during the primary procedure were categorized in the same fashion.
Diagnosis and catheter ablation of each arrhythmia was performed based on conventional protocols as previously described. 17 If employed, an ICE catheter is advanced to image the heart and is positioned in the right atrium. Diagnostic and ablation catheters are then advanced. The EnSite (ESI) system allows geometry to be created with any catheter and at any location in the body, including the iliac arteries and veins. No fluoroscopy was used during the manipulation of the catheters inside the aorta and inferior vena cava as they were visualized on the EnSite system from the time of exit from the short sheaths in the groin (Fig. 1) . When using Carto, a mapping catheter must be used to create geometry, then the other catheters may be advanced. The shell of the chamber(s) of interest is then created. The geometry created may then be used as a roadmap of the blood vessels and heart chambers. Catheter movement and positioning may then be performed with the EAM and ICE (if used). In cases where CARTO-Sound was used, the "green tip" feature was used to help confirm the ablation catheter tip location on ICE.
All patients were seen in outpatient followup. Phone calls, Holter monitor, event monitor, loop recorder, and/or cardiac implantable electronic devices (CIEDs) were employed to confirm efficacy.
Complications were defined as a procedurerelated event, either major or minor. A major complication was defined as an adverse event that required intervention for treatment. An "intervention" was defined as the need for an additional invasive procedure, such as pericardiocentesis, vascular surgery, or blood transfusion. A minor complication was defined as an adverse event that did not require an intervention and that could be managed on an outpatient basis.
Recurrence was defined as reappearance of an arrhythmia targeted for ablation as demonstrated by electrocardiogram (ECG), remote monitoring, or patient symptoms consistent with arrhythmia recurrence, with or without the need for repeat catheter ablation, from the date of the procedure. AF recurrence was defined in the same fashion following a 3-month blanking period.
Results
The study included 500 consecutive patients, with a total of 639 arrhythmias targeted for catheter ablation. The mean age was 60.8 years, the average body mass index was 30.3 kg/cm 2 , 305 patients were male, 220 were on a Vaughan Williams class I or III antiarrhythmic drug, and 66 had undergone prior ablation. A total of 52 patients had CIEDs, including cardiac resynchronization therapy devices. Patients with structural heart disease included 32 with valvular heart disease (four patients with mechanical mitral valves who underwent left atrial ablation), 61 with ischemic heart disease, 116 with cardiomyopathy, and one with cor triatriatum sinster (Table I) .
Major complications occurred in five patients (1.0%), and minor complications occurred in three patients (0.6%). No deaths occurred. Fluoroscopy was not used for catheter advancement or guidance in any case. Fluoroscopy was used in a single patient, for 0.3 minutes, to confirm venous access (Tables II-IV and Fig. 2) .
Atrioventricular Reciprocating Tachycardia
A total of 31 catheter ablations for AVRT were performed. Eleven accessory pathways were right sided, including three at the anterior or mid septum, and 20 were left sided. In this group, the mean procedure time was 125.1 minutes, with a range of 48-474 minutes. Acute procedural success was achieved in all 31 ablations. The average follow-up was 20.1 months and there were two recurrences (6.5%). There were no complications in this group. 
Atrioventricular Nodal Reentrant Tachycardia
Overall 79 catheter ablations of AVNRT were completed. RFA was used in nine cases; all others were performed with cryoablation. The mean procedure length was 113.2 minutes, with a range of 32-341 minutes. Acute procedural success was achieved in all 79 ablations. The average followup was 23.6 months; there were two recurrences (2.5%). There were no complications in this group.
Macro-Reentrant AT
A total of 188 catheter ablations for a macroreentrant AT were completed. Sites included 153 AF = atrial fibrillation; AVNRT = atrioventricular nodal reentrant tachycardia; AVRT = atrioventricular reciprocating tachycardia; AT = atrial tachycardia; PVC = premature ventricular contraction; VT = ventricular tachycardia. 
Focal AT
Overall, 111 catheter ablations for focal AT were performed. Of which, 39 were right sided, 42 were left sided, four were from noncoronary cusp, and 26 originated from the coronary sinus. The mean procedure length was 146.0 minutes, with a range of 54-371. Acute procedural success was achieved in all 111 ablations. The average follow-up was 18.4 months; there were six recurrences (5.4%). There was one major complication (1.7%), cardiac tamponade, requiring pericardiocentesis.
Atrial Fibrillation
A total of 186 catheter ablations for paroxysmal, persistent, and longstanding persistent AF were performed. A total of 156 patients (83.9%) underwent RF ablation, 30 patients (16.1%) underwent cryoballoon ablation. The mean procedure length was 194.4 minutes, with a range of 88-501 minutes. The average followup was 21.2 months; there were 42 recurrences (22.6%). There were three major complications (1.6%); two patients developed cardiac tamponade requiring pericardiocentesis and one patient developed an atrioesophageal fistula. There were three minor complications (1.6%); all were groin hematomas that did not require surgical intervention. Fluoroscopy was used during one case for 0.3 minutes for confirmation of venous access.
Premature Ventricular Contractions
Thirty catheter ablations for PVCs were performed. In the right ventricle, there were 10 right ventricular outflow tract PVCs, two peritricuspid valve annulus PVCs, and one paraHisian PVC. In the left ventricle, there were three left ventricular outflow tract PVCs, nine left ventricle base PVCs, two left coronary cusp PVCs, and three papillary muscle PVCs (two anteriorlateral and one postermedial). The mean procedure length was 201.9 minutes, with a range of 80-453 minutes. Acute procedural success was achieved in 28 patients (93.3%). The average follow-up was 14.2 months, and there were two recurrences (6.7%). There was one major complication (3.3%), cardiac tamponade requiring pericardiocentesis.
Ventricular Tachycardia
Fourteen catheter ablations for VT were completed. There were 10 ablations for ischemic VT with a mean left ventricular ejection fraction of 26.5%. There was one right ventricular outflow tract VT, one right coronary cusp VT, one fascicular VT, and one bundle branch reentry VT. The mean procedure length was 257.5 minutes, with a range of 130-462 minutes. Acute procedural success was achieved in all 14 patients. The average follow-up was 16.6 months, and there were three recurrences (21.4%). There were no complications in this group.
Discussion
In this study of 500 consecutive patients, we have shown that nonfluoroscopic catheter ablation of cardiac arrhythmias can be safely and effectively performed. Previously conducted studies have shown safety and efficacy. 17, 20, 21 Our complication rate is similar to those described for conventional ablations. [20] [21] [22] [23] [24] [25] The overall incidence of periprocedural complications following catheter ablation has been described as 2.9-3.8%. [22] [23] [24] [25] [26] [27] The type of ablation being performed confers different risks of complications, with AF and VT ablations having higher associated complication rates. 22, 26, 27 Overall our major complication rate was 1.0%. The complication rate in this case series was relatively low. The extensive use of ICE during the majority of our cases might have been a factor in monitoring for and preventing complications. There were five major complications; four were perforation with cardiac tamponade. Of the four cases of cardiac tamponade, two occurred during the ablation of the AF, one during ablation of left AT, and one during ablation of PVCs. Tamponade occurred during the AF and AT cases while RF energy was being delivered in the left atrium. The tamponade that occurred during the PVC ablation case happened on a patient with preexisting mild pericardial effusion. The patient developed cardiac tamponade shortly after he was given iliac vein (IV) heparin prior to insertion of any catheters into the LV or right ventricle. No clear reason was identified.
We had an occurrence of an atrioesophageal fistula. No esophageal temperature probe was used in this patient. Our strategy for esophageal injury prevention included monitoring of the esophagus on ICE and using brief bursts of RF energy delivery at low powers. Atrioesophageal fistulas are rare, occurring in 0.06-0.79% of AF ablations. 28 Our patient survived, following endoscopic and surgical intervention. No procedurerelated deaths occurred in this case series. This compares favorably with the literature. 22, 23, 25, 26 Accordingly, this experience provides additional evidence that a nonfluoroscopic approach does not add acute procedural risk.
Our average ablation length was 151.1 minutes with a range of 22-501 minutes. Ablations may typically last 2-4 hours depending on the arrhythmia or substrate targeted. The duration length, in part, is operator dependent, making this a difficult variable to compare. Our previous study compared 120 patients in a 1:1 ratio to fluoroscopic or nonfluoroscopic ablations; there were no significant procedural length differences between the two groups. 17 As shown in Figure 1 , our mean procedure time decreased as we gained more experience.
Our arrhythmia recurrences are in keeping with established recurrence rates for fluoroscopy directed ablations. 23, 25, 27, 29, 30 Long-term success rates for catheter ablation of AF were high at 78%. While data from ECG, event monitors, CIED interrogation, and loop recorders were used, some degree of follow-up bias cannot be excluded. Perhaps if loop recorders had been implanted in the majority of our patients, the long-term success rate may not have been as high.
Clinical Significance
Relying solely upon ICE and EAM has allowed us to maximize imaging potential of these techniques and better define the anatomy and tissue-catheter interface during the application of ablative energy. This has allowed us to accurately and rapidly define cardiac structures in all chambers. We have been able to reach and ensure contact with structures that fluoroscopy cannot delineate such as papillary muscles (Fig. 3) . Fluoroless ablation may be performed during complex ablations and with patients with uncommon anatomy. With ICE, we are able to define left atrial anatomy, including all pulmonary veins and any anomalies. Due to this increased proficiency with ICE, we have eliminated periprocedural cardiac computed tomography or magnetic resonance imaging for AF ablations in our lab. Our experience also includes left atrial ablations in patients with mechanical mitral valves (Fig. 4) , as well as a cryoballoon ablation of AF in a patient with cor triatriatum sinister.
Additionally, as fluoroscopy is not used, neither is IV contrast. For cryoballoon ablation of AF, 3D mapping and ICE were used. 3D mapping with the EnSite system was used to help determine the location of the Achieve mapping catheter. On ICE, longitudinal views of all pulmonary veins were obtained so that the balloon location could be easily visualized at the ostium. The balloon was inflated in the left atrium and outside of the pulmonary vein as seen on ICE. The balloon was then advanced toward the PV ostium just until a wedge wave form was first seen. Using this method, the balloon's location was confirmed to be not inside the pulmonary vein. Our experience also includes ablations in the coronary cusps. In this circumstance, the coronary ostia are defined on ICE, and thus avoided (Figs. 5 and 6 ).
Ionizing radiation is known to be teratogenic and carcinogenic; the reduction in its use has been a focus for many years. 9 The operator of a procedure involving ionizing radiation exposure has the responsibility to expose the patient and the staff to the lowest possible radiation dose needed to complete the procedure successfully, in accordance with the ALARA (as low as reasonably achievable) principle. Throughout this study, no catheters were positioned with the aid of fluoroscopy. Fluoroscopy was used in one case in order to confirm venous access, for a total of 0.3 minutes. Fluoroscopy times vary depending on the arrhythmia targeted. Using the conservative estimate of an average of 10 minutes of fluoroscopy time across all ablation types, we have saved 83 hours of continuous fluoroscopy time. Given the acute and cumulative effects of radiation, as well as the necessity to wear lead apparel, this is a significant number. Additionally, the fluoroscopy elimination has enabled pregnant staff members to still work in our lab. No staff members wear lead aprons during these procedures.
Limitations
Our study has several limitations. This is a single-center, single primary operator, and retrospective case series. As it was not a randomized multicenter control trial, it was therefore not intended to establish comparative safety and efficacy for widespread applicability. A randomized control trial would be needed to determine comparative safety and efficacy. While the contact of the catheter tip was seen using ICE, the amount of force could not be established as contact force-sensing catheters were not used. Contact force-sensing catheters were not used as the vast majority of procedures were performed using the St. Jude Medical EnSite system, which currently does not have a bidirectional contact force-sensing catheter. Using these catheters could have improved the safety of the procedures.
Conclusions
Fluoroless catheter ablation may be routinely performed for endocardial ablations across a broad spectrum of arrhythmias without compromising safety and efficacy or lengthening the duration of the procedure. Additionally, nonfluoroscopic ablation eliminates radiation exposure for all involved and may reduce the risk of orthopedic injury.
